Gedeon Richter buys rights to Mycenax bioanalogue tocilizumab

Gedeon Richter announced the conclusion of an agreement with the company Mycenax Biotech on the purchase of the rights to the bioanalogue tocilizumab for the treatment of rheumatoid arthritis.

Under the agreement, Gedeon Richter receives worldwide rights to develop, manufacture and commercialize bioanalogue tocilizumab. The deal includes the transfer of cell lines, intellectual property rights, technological know-how and data about a drug you have already received Mycenax.

The parties agreed that payment would be done Gedeon Richter in four tranches and will amount to 16.5 million dollars. The company has already made a prepayment in the amount of 2 million dollars for exclusivity in the negotiation process, at the signing of the contract will be paid another $ 3 million as a down payment. It is expected that the bioanalogue tocilizumab will appear on the markets of the European Union, Canada, Australia and Japan in 2025.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]